Pure Global AI
NCT06394167Not yet recruiting

A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single- and Multiple-dose Escalation Study Evaluating the Safety and Pharmacokinetics of Intravenous VX-993 in Healthy Adults
Vertex Pharmaceuticals IncorporatedPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Pain
Drug/Device/Intervention
VX-993
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Vertex Pharmaceuticals Incorporated
Timeline & enrollment
Phase
Phase 1
Start date
May 01, 2024
End date
May 01, 2025
Enrollment
110 participants
Primary outcome

Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK)
 of intravenously administered VX-993 at different doses in healthy participants.

ICD-10 classifications
Pain, unspecifiedPain, not elsewhere classifiedPain in limbAcute painOther chronic pain
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06394167
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06394167 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vertex Pharmaceuticals Incorporated and is currently Not yet recruiting. The study focuses on Pain. Target enrollment is 110 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.